SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Reff, M. Articles by Anderson, D. Search for Related Content PubMed PubMed Citation Articles by Reff, M. Articles by Anderson, D. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, RA Newman, N Hanna and DR Anderson IDEC Pharmaceuticals Corporation, San Diego, CA 92121. Murine monoclonal antibody 2B8 specifically recognizes the CD20 phosphoprotein expressed on the surface of normal B lymphocytes and B- cell lymphomas. The light- and heavy-chain variable regions of 2B8 were cloned, after amplification by the polymerase chain reaction, into a cDNA expression vector that contained human IgG1 heavy chain and human kappa-light chain constant regions. High-level expression of chimeric- 2B8 antibody (C2B8) was obtained in Chinese hamster ovary cells. Purified C2B8 exhibited antigen binding affinity and human-tissue reactivity similar to the native murine antibody. In vitro studies showed the ability of C2B8 to bind human C1q, mediate complement- dependent cell lysis of human B-lymphoid cell lines, and lyse human target cells through antibody-dependent cellular cytotoxicity. Infusion of macaque cynomolgus monkeys with doses ranging from 1.6 mg/kg to 6.4 mg/kg resulted in greater than 98% depletion of peripheral blood (PB) B cells and 40% to 70% depletion of lymph node B cells. Recovery of PB B cells usually started at 2 weeks after treatment and required 60 to greater than 90 days to reach normal levels. As much as 95% depletion of B cells in peripheral lymph nodes and bone marrow was observed following weekly injections of 16.8 mg/kg antibody. No toxicity was observed in any of the animals. These results offer the possibility of using an "immunologically active" chimeric anti-CD20 antibody as an alternative approach in the treatment of B-cell lymphoma. Volume 83, Issue 2, pp. 435-445, 01/15/1994 Copyright © 1994 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Li, L. Zhao, H. Guo, C. Wang, X. Zhang, L. Wu, L. Chen, Q. Tong, W. Qian, H. Wang, et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma Blood, December 3, 2009; 114(24): 5007 - 5015. [Abstract] [Full Text] [PDF] M. D. Pescovitz, C. J. Greenbaum, H. Krause-Steinrauf, D. J. Becker, S. E. Gitelman, R. Goland, P. A. Gottlieb, J. B. Marks, P. F. McGee, A. M. Moran, et al. Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function N. Engl. J. Med., November 26, 2009; 361(22): 2143 - 2152. [Abstract] [Full Text] [PDF] M. I. Vega, S. Huerta-Yepez, M. Martinez-Paniagua, B. Martinez-Miguel, R. Hernandez-Pando, C. R. Gonzalez-Bonilla, P. Chinn, N. Hanna, K. Hariharan, A. R. Jazirehi, et al. Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions Clin. Cancer Res., November 1, 2009; 15(21): 6582 - 6594. [Abstract] [Full Text] [PDF] S. A. Gregory, K. Hohloch, C. Gisselbrecht, K. Tobinai, and M. Dreyling Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma Oncologist, October 1, 2009; 14(suppl_2): 4 - 16. [Abstract] [Full Text] [PDF] S. A. Maxwell, Z. Li, D. Jaya, S. Ballard, J. Ferrell, and H. Fu 14-3-3{zeta} Mediates Resistance of Diffuse Large B Cell Lymphoma to an Anthracycline-based Chemotherapeutic Regimen J. Biol. Chem., August 14, 2009; 284(33): 22379 - 22389. [Abstract] [Full Text] [PDF] A. W. Pawluczkowycz, F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. J. van de Winkel, P. W. H. I. Parren, and R. P. Taylor Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX J. Immunol., July 1, 2009; 183(1): 749 - 758. [Abstract] [Full Text] [PDF] J. Gertner-Dardenne, C. Bonnafous, C. Bezombes, A.-H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J.-F. Lepage, A. Quillet-Mary, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies Blood, May 14, 2009; 113(20): 4875 - 4884. [Abstract] [Full Text] [PDF] L. MANOLOPOULOS, I. P GOMATOS, E. LEANDROS, L. ALEVIZOS, N. GEORGIOU, J. GIOTAKIS, and E. FEREKIDIS Use of Rituximab in Combination with Conventional Chemotherapy for the Treatment of Non-Hodgkin's Lymphoma of the Head and Neck In Vivo, May 1, 2009; 23(3): 475 - 478. [Abstract] [Full Text] [PDF] J. Zalevsky, I. W. L. Leung, S. Karki, S. Y. Chu, E. A. Zhukovsky, J. R. Desjarlais, D. F. Carmichael, and C. E. Lawrence The impact of Fc engineering on an anti-CD19 antibody: increased Fc{gamma} receptor affinity enhances B-cell clearing in nonhuman primates Blood, April 16, 2009; 113(16): 3735 - 3743. [Abstract] [Full Text] [PDF] S. P. Hilchey, O. Hyrien, T. R. Mosmann, A. M. Livingstone, J. W. Friedberg, F. Young, R. I. Fisher, R. J. Kelleher Jr, R. B. Bankert, and S. H. Bernstein Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab Blood, April 16, 2009; 113(16): 3809 - 3812. [Abstract] [Full Text] [PDF] T. Tanaka and T. H. Rabbitts Selection of complementary single-variable domains for building monoclonal antibodies to native proteins Nucleic Acids Res., April 1, 2009; 37(5): e41 - e41. [Abstract] [Full Text] [PDF] E Keystone, P Emery, C G Peterfy, P P Tak, S Cohen, M C Genovese, M Dougados, G R Burmester, M Greenwald, T K Kvien, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies Ann Rheum Dis, February 1, 2009; 68(2): 216 - 221. [Abstract] [Full Text] [PDF] K. A Heemstra, R. E Toes, J. Sepers, A. M Pereira, E. P Corssmit, T. W J Huizinga, J. A Romijn, and J. W Smit Rituximab in relapsing Graves' disease, a phase II study Eur. J. Endocrinol., November 1, 2008; 159(5): 609 - 615. [Abstract] [Full Text] [PDF] K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al. Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., October 1, 2008; 26(28): 4587 - 4594. [Abstract] [Full Text] [PDF] M. J. Mattes, R. M. Sharkey, H. Karacay, M. S. Czuczman, and D. M. Goldenberg Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab) Clin. Cancer Res., October 1, 2008; 14(19): 6154 - 6160. [Abstract] [Full Text] [PDF] C B Driver, M Ishimori, and M H Weisman The B cell in systemic lupus erythaematosus: a rational target for more effective therapy Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381. [Abstract] [Full Text] [PDF] B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood, H. A. Greisman, X. Qian, S. E. James, A. Raubitschek, S. J. Forman, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood, September 15, 2008; 112(6): 2261 - 2271. [Abstract] [Full Text] [PDF] A. J. Ferraro, S. W. Smith, D. Neil, and C. O.S. Savage Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood Nephrol. Dial. Transplant., September 1, 2008; 23(9): 3030 - 3032. [Abstract] [Full Text] [PDF] P. V. Beum, M. A. Lindorfer, and R. P. Taylor Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving J. Immunol., August 15, 2008; 181(4): 2916 - 2924. [Abstract] [Full Text] [PDF] V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV Blood, August 15, 2008; 112(4): 1205 - 1213. [Abstract] [Full Text] [PDF] A Ruckert, H Glimm, M Lubbert, and C Grullich Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up Lupus, August 1, 2008; 17(8): 757 - 760. [Abstract] [PDF] A. K. Gopal, O. W. Press, S. M. Wilbur, D. G. Maloney, and J. M. Pagel Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab Blood, August 1, 2008; 112(3): 830 - 835. [Abstract] [Full Text] [PDF] A. A. Vo, M. Lukovsky, M. Toyoda, J. Wang, N. L. Reinsmoen, C.-H. Lai, A. Peng, R. Villicana, and S. C. Jordan Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation N. Engl. J. Med., July 17, 2008; 359(3): 242 - 251. [Abstract] [Full Text] [PDF] K. Shimada, K. Matsue, K. Yamamoto, T. Murase, N. Ichikawa, M. Okamoto, N. Niitsu, H. Kosugi, N. Tsukamoto, H. Miwa, et al. Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan J. Clin. Oncol., July 1, 2008; 26(19): 3189 - 3195. [Abstract] [Full Text] [PDF] P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis J. Immunol., July 1, 2008; 181(1): 822 - 832. [Abstract] [Full Text] [PDF] G. Cartron, L. Zhao-Yang, M. Baudard, T. Kanouni, V. Rouille, P. Quittet, B. Klein, and J.-F. Rossi Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study J. Clin. Oncol., June 1, 2008; 26(16): 2725 - 2731. [Abstract] [Full Text] [PDF] E. Kondo, T. Tanaka, T. Miyake, T. Ichikawa, M. Hirai, M. Adachi, K. Yoshikawa, K. Ichimura, N. Ohara, A. Moriwaki, et al. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines Mol. Cancer Ther., June 1, 2008; 7(6): 1461 - 1471. [Abstract] [Full Text] [PDF] J. Chen, C. Su, Q. Lu, W. Shi, Q. Zhang, X. Wang, J. Long, Q. Yang, L. Li, X. Jia, et al. Generation of adenovirus-mediated anti-CD20 antibody and its effect on B-cell deletion in mice and nonhuman primate cynomolgus monkey Mol. Cancer Ther., June 1, 2008; 7(6): 1562 - 1568. [Abstract] [Full Text] [PDF] G. Kurosawa, Y. Akahori, M. Morita, M. Sumitomo, N. Sato, C. Muramatsu, K. Eguchi, K. Matsuda, A. Takasaki, M. Tanaka, et al. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic PNAS, May 20, 2008; 105(20): 7287 - 7292. [Abstract] [Full Text] [PDF] A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, et al. Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities Cancer Res., May 15, 2008; 68(10): 3863 - 3872. [Abstract] [Full Text] [PDF] D. Isenberg Treating patients with lupus with B-cell depletion Lupus, May 1, 2008; 17(5): 400 - 404. [Abstract] [PDF] D. E. Fassi, C. H Nielsen, J. Kjeldsen, O. Clemmensen, and L. Hegedus Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease Gut, May 1, 2008; 57(5): 714 - 715. [Full Text] [PDF] M. Baba, M. Okamoto, T. Hamasaki, S. Horai, X. Wang, Y. Ito, Y. Suda, and N. Arima Highly Enhanced Expression of CD70 on Human T-Lymphotropic Virus Type 1-Carrying T-Cell Lines and Adult T-Cell Leukemia Cells J. Virol., April 15, 2008; 82(8): 3843 - 3852. [Abstract] [Full Text] [PDF] B. Li, S. Shi, W. Qian, L. Zhao, D. Zhang, S. Hou, L. Zheng, J. Dai, J. Zhao, H. Wang, et al. Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity Cancer Res., April 1, 2008; 68(7): 2400 - 2408. [Abstract] [Full Text] [PDF] N. S. Kapadia, J. M. Engles, and R. L. Wahl In Vitro Evaluation of Radioprotective and Radiosensitizing Effects of Rituximab J. Nucl. Med., April 1, 2008; 49(4): 674 - 678. [Abstract] [Full Text] [PDF] S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al. B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis N. Engl. J. Med., February 14, 2008; 358(7): 676 - 688. [Abstract] [Full Text] [PDF] N. I. Pathan, P. Chu, K. Hariharan, C. Cheney, A. Molina, and J. Byrd Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines Blood, February 1, 2008; 111(3): 1594 - 1602. [Abstract] [Full Text] [PDF] E. Bremer, B. ten Cate, D. F. Samplonius, N. Mueller, H. Wajant, A. J. Stel, M. Chamuleau, A. A. van de Loosdrecht, J. Stieglmaier, G. H. Fey, et al. Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists Cancer Res., January 15, 2008; 68(2): 597 - 604. [Abstract] [Full Text] [PDF] J. M. Vose Maintenance Rituximab-Should It Be Given to Every Patient with Follicular Lymphoma? ASCO Educational Book, January 1, 2008; 2008(1): 386 - 390. [Abstract] [Full Text] [PDF] S. Berentsen Rituximab for the treatment of autoimmune cytopenias Haematologica, December 1, 2007; 92(12): 1589 - 1596. [Full Text] [PDF] P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab Cancer Res., November 1, 2007; 67(21): 10556 - 10563. [Abstract] [Full Text] [PDF] J. B. Stavenhagen, S. Gorlatov, N. Tuaillon, C. T. Rankin, H. Li, S. Burke, L. Huang, S. Johnson, E. Bonvini, and S. Koenig Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc{gamma} Receptors Cancer Res., September 15, 2007; 67(18): 8882 - 8890. [Abstract] [Full Text] [PDF] Y. Li, M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models J. Immunol., September 15, 2007; 179(6): 4263 - 4271. [Abstract] [Full Text] [PDF] P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma Clin. Cancer Res., September 15, 2007; 13(18): 5636s - 5642s. [Abstract] [Full Text] [PDF] A. Ahuja, J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik Depletion of B Cells in Murine Lupus: Efficacy and Resistance J. Immunol., September 1, 2007; 179(5): 3351 - 3361. [Abstract] [Full Text] [PDF] T M El-Shanawany, P E Williams, and S Jolles Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab J. Clin. Pathol., June 1, 2007; 60(6): 715 - 716. [Full Text] [PDF] M. Herold, A. Haas, S. Srock, S. Neser, K. H. Al-Ali, A. Neubauer, G. Dolken, R. Naumann, W. Knauf, M. Freund, et al. Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study J. Clin. Oncol., May 20, 2007; 25(15): 1986 - 1992. [Abstract] [Full Text] [PDF] J. Du, H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab J. Biol. Chem., May 18, 2007; 282(20): 15073 - 15080. [Abstract] [Full Text] [PDF] J. G. Berdeja, A. Hess, D. M. Lucas, P. O'Donnell, R. F. Ambinder, L. F. Diehl, D. Carter-Brookins, S. Newton, and I. W. Flinn Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab Clin. Cancer Res., April 15, 2007; 13(8): 2392 - 2399. [Abstract] [Full Text] [PDF] S. Nomura, K. Ishii, Y. Kamitsuji, N. Uoshima, E. Ishikawa, H. Kitayama, and K. Hayashi Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)-Treated Non-Hodgkin's Lymphoma Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 206 - 212. [Abstract] [PDF] M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system Ann Rheum Dis, April 1, 2007; 66(4): 470 - 475. [Abstract] [Full Text] [PDF] H. Singh, L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, et al. Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy Cancer Res., March 15, 2007; 67(6): 2872 - 2880. [Abstract] [Full Text] [PDF] J. Kurai, H. Chikumi, K. Hashimoto, K. Yamaguchi, A. Yamasaki, T. Sako, H. Touge, H. Makino, M. Takata, M. Miyata, et al. Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines Clin. Cancer Res., March 1, 2007; 13(5): 1552 - 1561. [Abstract] [Full Text] [PDF] A. R. Jazirehi, M. I. Vega, and B. Bonavida Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy Cancer Res., February 1, 2007; 67(3): 1270 - 1281. [Abstract] [Full Text] [PDF] C. F. Wong Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol. Dial. Transplant., January 1, 2007; 22(1): 32 - 36. [Full Text] [PDF] M. J. Leandro, N. Cooper, G. Cambridge, M. R. Ehrenstein, and J. C. W. Edwards Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy Rheumatology, January 1, 2007; 46(1): 29 - 36. [Abstract] [Full Text] [PDF] M. H. J. van Oers, R. Klasa, R. E. Marcus, M. Wolf, E. Kimby, R. D. Gascoyne, A. Jack, M. van't Veer, A. Vranovsky, H. Holte, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Blood, November 15, 2006; 108(10): 3295 - 3301. [Abstract] [Full Text] [PDF] S. M. Ansell, S. M. Geyer, M. J. Maurer, P. J. Kurtin, I. N.M. Micallef, P. Stella, P. Etzell, A. J. Novak, C. Erlichman, and T. E. Witzig Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. Clin. Cancer Res., October 15, 2006; 12(20): 6056 - 6063. [Abstract] [Full Text] [PDF] D. H. Kim, H. D. Jung, J. G. Kim, J.-J. Lee, D.-H. Yang, Y. H. Park, Y. R. Do, H. J. Shin, M. K. Kim, M. S. Hyun, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma Blood, October 15, 2006; 108(8): 2720 - 2725. [Abstract] [Full Text] [PDF] R. Stein, Z. Qu, S. Chen, D. Solis, H. J. Hansen, and D. M. Goldenberg Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab Blood, October 15, 2006; 108(8): 2736 - 2744. [Abstract] [Full Text] [PDF] D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options Blood, September 1, 2006; 108(5): 1451 - 1460. [Abstract] [Full Text] [PDF] J. Elgqvist, H. Andersson, T. Back, I. Claesson, R. Hultborn, H. Jensen, B. R. Johansson, S. Lindegren, M. Olsson, S. Palm, et al. {alpha}-Radioimmunotherapy of Intraperitoneally Growing OVCAR-3 Tumors of Variable Dimensions: Outcome Related to Measured Tumor Size and Mean Absorbed Dose J. Nucl. Med., August 1, 2006; 47(8): 1342 - 1350. [Abstract] [Full Text] [PDF] R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF] O Flossmann, R B Jones, D R W Jayne, and R A Luqmani Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis, July 1, 2006; 65(7): 841 - 844. [Full Text] [PDF] L. Quartuccio, G. Soardo, G. Romano, F. Zaja, C. A. Scott, G. De Marchi, M. Fabris, G. Ferraccioli, and S. De Vita Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids Rheumatology, July 1, 2006; 45(7): 842 - 846. [Abstract] [Full Text] [PDF] D. El Fassi, C. H Nielsen, H. C Hasselbalch, and L. Hegedus The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur. J. Endocrinol., May 1, 2006; 154(5): 623 - 632. [Abstract] [Full Text] [PDF] C. Kelly-Quintos, L. A. Cavacini, M. R. Posner, D. Goldmann, and G. B. Pier Characterization of the Opsonic and Protective Activity against Staphylococcus aureus of Fully Human Monoclonal Antibodies Specific for the Bacterial Surface Polysaccharide Poly-N-Acetylglucosamine. Infect. Immun., May 1, 2006; 74(5): 2742 - 2750. [Abstract] [Full Text] [PDF] S. Iida, H. Misaka, M. Inoue, M. Shibata, R. Nakano, N. Yamane-Ohnuki, M. Wakitani, K. Yano, K. Shitara, and M. Satoh Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to Fc{gamma}RIIIa. Clin. Cancer Res., May 1, 2006; 12(9): 2879 - 2887. [Abstract] [Full Text] [PDF] J. Kriangkum, B. J. Taylor, E. Strachan, M. J. Mant, T. Reiman, A. R. Belch, and L. M. Pilarski Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery Blood, April 1, 2006; 107(7): 2920 - 2927. [Abstract] [Full Text] [PDF] Y. Hamaguchi, Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder Antibody isotype-specific engagement of Fc{gamma} receptors regulates B lymphocyte depletion during CD20 immunotherapy J. Exp. Med., March 20, 2006; 203(3): 743 - 753. [Abstract] [Full Text] [PDF] G. A. Lazar, W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. Engineered antibody Fc variants with enhanced effector function. PNAS, March 14, 2006; 103(11): 4005 - 4010. [Abstract] [Full Text] [PDF] R. H. Carter B Cells in Health and Disease Mayo Clin. Proc., March 1, 2006; 81(3): 377 - 384. [Abstract] [Full Text] [PDF] Y. Vugmeyster, D. Seshasayee, W. Chang, A. Storn, K. Howell, S. Sa, T. Nelson, F. Martin, I. Grewal, E. Gilkerson, et al. A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells and Lymphoid Tissue Marginal Zone and Follicular B Cells in Cynomolgus Monkeys Am. J. Pathol., February 1, 2006; 168(2): 476 - 489. [Abstract] [Full Text] [PDF] W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood, December 1, 2005; 106(12): 3725 - 3732. [Abstract] [Full Text] [PDF] K. Saito, M. Nawata, S. Iwata, M. Tokunaga, and Y. Tanaka Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus Rheumatology, November 1, 2005; 44(11): 1462 - 1464. [Full Text] [PDF] W. G. Wierda, T. J. Kipps, and M. J. Keating Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332. [Abstract] [Full Text] [PDF] W. Hiddemann, C. Buske, M. Dreyling, O. Weigert, G. Lenz, R. Forstpointner, C. Nickenig, and M. Unterhalt Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives J. Clin. Oncol., September 10, 2005; 23(26): 6394 - 6399. [Abstract] [Full Text] [PDF] D. G. Maloney Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines J. Clin. Oncol., September 10, 2005; 23(26): 6421 - 6428. [Abstract] [Full Text] [PDF] M. I. Vega, A. R. Jazirehi, S. Huerta-Yepez, and B. Bonavida Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin's Lymphoma Cell Line via Inhibition of NF-{kappa}B Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively J. Immunol., August 15, 2005; 175(4): 2174 - 2183. [Abstract] [Full Text] [PDF] N. Zhang, L. A. Khawli, P. Hu, and A. L. Epstein Generation of Rituximab Polymer May Cause Hyper-Cross-linking-Induced Apoptosis in Non-Hodgkin's Lymphomas Clin. Cancer Res., August 15, 2005; 11(16): 5971 - 5980. [Abstract] [Full Text] [PDF] J. S. Abramson and M. A. Shipp Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood, August 15, 2005; 106(4): 1164 - 1174. [Abstract] [Full Text] [PDF] L. H. Sehn, J. Donaldson, M. Chhanabhai, C. Fitzgerald, K. Gill, R. Klasa, N. MacPherson, S. O'Reilly, J. J. Spinelli, J. Sutherland, et al. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia J. Clin. Oncol., August 1, 2005; 23(22): 5027 - 5033. [Abstract] [Full Text] [PDF] K. Dunleavy, F. Hakim, H. K. Kim, J. E. Janik, N. Grant, T. Nakayama, T. White, G. Wright, L. Kwak, R. Gress, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis Blood, August 1, 2005; 106(3): 795 - 802. [Abstract] [Full Text] [PDF] T. Doan and E. Massarotti Rheumatoid Arthritis: An Overview of New and Emerging Therapies J. Clin. Pharmacol., July 1, 2005; 45(7): 751 - 762. [Abstract] [Full Text] [PDF] D. Yu, M. Dews, A. Park, J. W. Tobias, and A. Thomas-Tikhonenko Inactivation of Myc in Murine Two-Hit B lymphomas Causes Dormancy with Elevated Levels of Interleukin 10 Receptor and CD20: Implications for Adjuvant Therapies Cancer Res., June 15, 2005; 65(12): 5454 - 5461. [Abstract] [Full Text] [PDF] W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms J. Immunol., June 15, 2005; 174(12): 7859 - 7868. [Abstract] [Full Text] [PDF] M. J. Rummel, S. E. Al-Batran, S.-Z. Kim, M. Welslau, R. Hecker, D. Kofahl-Krause, K.-M. Josten, H. Durk, A. Rost, M. Neise, et al. Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma J. Clin. Oncol., May 20, 2005; 23(15): 3383 - 3389. [Abstract] [Full Text] [PDF] Y. Hamaguchi, J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice J. Immunol., April 1, 2005; 174(7): 4389 - 4399. [Abstract] [Full Text] [PDF] S A Chambers and D Isenberg Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases Lupus, March 1, 2005; 14(3): 210 - 214. [Abstract] [PDF] L. N. Gordan, W. B. Grow, A. Pusateri, V. Douglas, N. P. Mendenhall, and J. W. Lynch Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative Disorders J. Clin. Oncol., February 20, 2005; 23(6): 1096 - 1102. [Abstract] [Full Text] [PDF] M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson, Z.P. Bernstein, P. McCarthy, A. Alam, F. Hernandez-Ilizaliturri, et al. Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma J. Clin. Oncol., February 1, 2005; 23(4): 694 - 704. [Abstract] [Full Text] [PDF] S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab J. Clin. Oncol., February 1, 2005; 23(4): 712 - 719. [Abstract] [Full Text] [PDF] M. Tokunaga, K. Fujii, K. Saito, S. Nakayamada, S. Tsujimura, M. Nawata, and Y. Tanaka Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab Rheumatology, February 1, 2005; 44(2): 176 - 182. [Abstract] [Full Text] [PDF] Q. Gong, Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy J. Immunol., January 15, 2005; 174(2): 817 - 826. [Abstract] [Full Text] [PDF] R. B. Michel, A. V. Rosario, P. M. Andrews, D. M. Goldenberg, and M. J. Mattes Therapy of Small Subcutaneous B-Lymphoma Xenografts with Antibodies Conjugated to Radionuclides Emitting Low-Energy Electrons Clin. Cancer Res., January 15, 2005; 11(2): 777 - 786. [Abstract] [Full Text] [PDF] J. W. Friedberg, H. Kim, M. McCauley, E. M. Hessel, P. Sims, D. C. Fisher, L. M. Nadler, R. L. Coffman, and A. S. Freedman Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-{alpha}/{beta}-inducible gene expression, without significant toxicity Blood, January 15, 2005; 105(2): 489 - 495. [Abstract] [Full Text] [PDF] H Tahir and D A Isenberg Novel therapies in lupus nephritis Lupus, January 1, 2005; 14(1): 77 - 82. [Abstract] [PDF]

	Copyright © 1994 by American Society of Hematology         Online ISSN: 1528-0020